Developing drugs for core social and communication impairment in autism.
about
The association of GPR85 with PSD-95-neuroligin complex and autism spectrum disorder: a molecular analysisAutismBehavioural phenotyping assays for mouse models of autismRepetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.New directions in the treatment of autism spectrum disorders from animal model research.Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome.A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorderAn investigation of plasma and salivary oxytocin responses in breast- and formula-feeding mothers of infantsAn open-label naturalistic pilot study of acamprosate in youth with autistic disorder.Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disordersA randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disordersPharmacotherapy for the core symptoms in autistic disorder: current status of the researchComparing oxytocin and cortisol regulation in a double-blind, placebo-controlled, hydrocortisone challenge pilot study in children with autism and typical development.Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysisThe Potential of Nasal Oxytocin Administration for Remediation of Autism Spectrum Disorders.Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families.Issues in the management of challenging behaviours of adults with autism spectrum disorder.What's in the pipeline? Drugs in development for autism spectrum disorder.Autism biomarkers: challenges, pitfalls and possibilities.Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study.Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [(18)F]setoperone PET study.STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.Brief report: Platelet-poor plasma serotonin in autism.
P2860
Q24322902-43C4EBEE-6E7C-43BE-8790-912F03E47191Q24629445-BA972487-DF08-4608-BE06-8C1B31C6AFE4Q29618414-58766810-053E-4DB4-9C35-3AE667404A89Q33685348-231FD9EC-9F84-4575-8271-9444B03AD43FQ34073325-8FD97314-7B76-4A72-A053-167805F6EA92Q34267391-419CC9D5-0C95-44BB-AA8A-57395ACD709FQ34449331-BBB68218-FEF0-4C19-B0A3-AAB45E6C8A3DQ35162921-36B767EE-BF10-43A9-A7B5-25984F26ACE0Q35597395-C4605910-57FA-4BAA-AA56-7C70AEF614B5Q35625886-CABC363E-3EC1-4F6E-B241-A98EA98EA66EQ35829853-D1EC8759-22DF-4E6F-B1AD-23832679AF7EQ36461648-27A3ED7F-C8A9-40F8-84E4-500C3FCE9657Q36784208-5B8B6D4F-9C67-474F-A273-574199ED3A4DQ37185279-23C6DA3D-4AAE-41DF-92B0-8371DCE081F3Q37347743-6B3F7298-4549-4A18-BF35-E3735369F2DBQ37367588-609EF7D0-9447-4D0B-8C47-81C391A03E4BQ37454964-5111841A-A4B4-4113-AC78-DACC21F6E752Q37774100-6E5F4466-034E-4ED2-9936-04188650F727Q37893637-F5FC89BE-FDE5-4322-888D-F36CCE9490E1Q38193069-21181E93-B3A9-43D8-BF87-8E759CE49561Q38246388-F0D09B40-CB83-4420-A33D-03EE67B345D8Q38348189-7F9DF514-0C7C-45F1-BC4B-520962616485Q39347371-C032082E-0C50-4F90-B667-125F1D46EED1Q43144400-337C38CE-7EA0-455E-A33A-A750057AC340Q47952892-0CF44AEE-7D8F-4D39-9F24-26BBECE3D93EQ50346151-EC80C560-03AF-40E4-BD8B-16191F7A9DF8
P2860
Developing drugs for core social and communication impairment in autism.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Developing drugs for core social and communication impairment in autism.
@ast
Developing drugs for core social and communication impairment in autism.
@en
Developing drugs for core social and communication impairment in autism.
@nl
type
label
Developing drugs for core social and communication impairment in autism.
@ast
Developing drugs for core social and communication impairment in autism.
@en
Developing drugs for core social and communication impairment in autism.
@nl
prefLabel
Developing drugs for core social and communication impairment in autism.
@ast
Developing drugs for core social and communication impairment in autism.
@en
Developing drugs for core social and communication impairment in autism.
@nl
P2860
P1476
Developing drugs for core social and communication impairment in autism.
@en
P2093
Craig A Erickson
David J Posey
P2860
P304
787-801, viii-ix
P356
10.1016/J.CHC.2008.06.010
P577
2008-10-01T00:00:00Z